Wein, Marc N.
Liang, Yanke
Goransson, Olga
Sundberg, Thomas B.
Wang, Jinhua
Williams, Elizabeth A.
O’Meara, Maureen J.
Govea, Nicolas
Beqo, Belinda
Nishimori, Shigeki
Nagano, Kenichi
Brooks, Daniel J.
Martins, Janaina S.
Corbin, Braden
Anselmo, Anthony
Sadreyev, Ruslan
Wu, Joy Y.
Sakamoto, Kei
Foretz, Marc
Xavier, Ramnik J.
Baron, Roland
Bouxsein, Mary L.
Gardella, Thomas J.
Divieti-Pajevic, Paola
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Kronenberg, Henry M.
Article History
Received: 7 March 2016
Accepted: 9 September 2016
First Online: 19 October 2016
Change Date: 22 February 2017
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Competing interests
: Y.L. and N.G. are co-inventors of YKL-04-114, YKL-05-093 and YKL-05-099. H.M.K. receives grant support from Amgen, and has received consulting honorariums from Amgen and Novartis. M.B. receives grant support from Amgen and Merck, and serves on scientific advisory boards for Merck and Eli Lilly. T.S., R.X., H.M.K., and M.N.W. declare that patents have been filed for the therapeutic application of SIK inhibitors. The remaining authors declare no competing financial interests.